Infectome: A platform to trace infectious triggers of autoimmunity

Autoimmunity Reviews

Volumn 12, Issue 7, 2013, Pages 726-740

  Bogdanos, Dimitrios P ^a,b   Smyk, Daniel S ^a   Invernizzi, Pietro ^c   Rigopoulou, Eirini I ^b   Blank, Miri ^d   Pouria, Shideh ^a   Shoenfeld, Yehuda ^d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF THESSALY   (Greece)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d SHEBA MEDICAL CENTER   (Israel)

Author keywords

Autoantibodies; Autoimmune disease; Autoimmunity; Environment; Immunity; Infection; Microbiome

Indexed keywords

AUTOIMMUNE DISEASE; AUTOIMMUNITY; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EUKARYOTIC CELL; EXPOSOME; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; INFECTION; INFECTOME; INTESTINE FLORA; MICROBIOME; MICROORGANISM; MOLECULAR BIOLOGY; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PRIMARY BILIARY CIRRHOSIS; REVIEW; SEROLOGY; SYMBIOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; COMMUNICABLE DISEASES; HUMANS; PROTEOME;

EID: 84877795494     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.12.005     Document Type: Review

References (420)

1. Gourley M., Miller F.W. Mechanisms of disease: environmental factors in the pathogenesis of rheumatic disease. Nat Clin Pract Rheumatol 2007, 3:172-180.
2. Lettre G., Rioux J.D. Autoimmune diseases: insights from genome-wide association studies. Hum Mol Genet 2008, 17:R116-R121.
3. Rappaport S.M., Smith M.T. Epidemiology. Environment and disease risks. Science 2010, 330:460-461.
4. Kivity S., Agmon-Levin N., Blank M., Shoenfeld Y. Infections and autoimmunity-friends or foes?. Trends Immunol 2009, 30:409-414.
5. Jacobson D.L., Gange S.J., Rose N.R., Graham N.M. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997, 84:223-243.
6. Blank M., Gershwin M.E. Autoimmunity: from the mosaic to the kaleidoscope. J Autoimmun 2008, 30:1-4.
7. Brickman C.M., Shoenfeld Y. The mosaic of autoimmunity. Scand J Clin Lab Invest Suppl 2001, 235:3-15.
8. Rahamim-Cohen D., Shoenfeld Y. The mosaic of autoimmunity. A classical case of inhalation of a polyclonal activating factor in a genetically and hormonally susceptible patient leading to multiple autoimmune diseases. Isr Med Assoc J 2001, 3:381-382.
9. Shepshelovich D., Shoenfeld Y. Prediction and prevention of autoimmune diseases: additional aspects of the mosaic of autoimmunity. Lupus 2006, 15:183-190.
10. Shoenfeld Y., Blank M., Abu-Shakra M., Amital H., Barzilai O., Berkun Y., et al. The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases-2008. Isr Med Assoc J 2008, 10:13-19.
11. Shoenfeld Y., Gilburd B., Abu-Shakra M., Amital H., Barzilai O., Berkun Y., et al. The mosaic of autoimmunity: genetic factors involved in autoimmune diseases-2008. Isr Med Assoc J 2008, 10:3-7.
12. Asherson R.A., Gunter K., Daya D., Shoenfeld Y. Multiple autoimmune diseases in a young woman: tuberculosis and splenectomy as possible triggering factors? Another example of the "mosaic" of autoimmunity. J Rheumatol 2008, 35:1224-1226.
13. de Carvalho J.F., Pereira R.M., Shoenfeld Y. The mosaic of autoimmunity: the role of environmental factors. Front Biosci (Elite Ed) 2009, 1:501-509.
14. Costenbader K.H., Gay S., Alarcon-Riquelme M.E., Iaccarino L., Doria A. Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases?. Autoimmun Rev 2012, 11:604-609.
15. Mavropoulos A., Orfanidou T., Liaskos C., Smyk D.S., Billinis C., Blank M., et al. p38 mitogen-activated protein kinase (p38 MAPK)-mediated autoimmunity: lessons to learn from ANCA vasculitis and pemphigus vulgaris. Autoimmun Rev Nov 30 2012, http://dx.doi.org/10.1016/j.autrev.2012.10.019. [pii: S1568-9972(12)00277-7. Electronic publication ahead of print PMID:23207287].
16. Karlson E.W., Deane K. Environmental and gene-environment interactions and risk of rheumatoid arthritis. Rheum Dis Clin North Am 2012, 38:405-426.
17. Villeda S.A., Wyss-Coray T. The circulatory systemic environment as a modulator of neurogenesis and brain aging. Autoimmun Rev Nov 29 2012, http://dx.doi.org/10.1016/j.autrev.2012.10.014 [pii: S1568-9972(12)00272-8. Electronic publication ahead of print PMID: 23201925].
18. Simon K.C., van der Mei I.A., Munger K.L., Ponsonby A., Dickinson J., Dwyer T., et al. Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on multiple sclerosis risk. Neurology 2010, 74:1365-1371.
19. Gatto M., Zen M., Ghirardello A., Bettio S., Bassi N., Iaccarino L., et al. Emerging and critical issues in the pathogenesis of lupus. Autoimmun Rev Sep 18 2012, http://dx.doi.org/10.1016/j.autrev.2012.09.003 [pii: S1568-9972(12)00213-3. Electronic publication ahead of print PMID: 23000207].
20. Selmi C., Leung P.S., Sherr D.H., Diaz M., Nyland J.F., Monestier M., et al. Mechanisms of environmental influence on human autoimmunity: a national institute of environmental health sciences expert panel workshop. J Autoimmun 2012, 39:272-284.
21. Bogdanos D.P., Smith H., Ma Y., Baum H., Mieli-Vergani G., Vergani D. A study of molecular mimicry and immunological cross-reactivity between hepatitis B surface antigen and myelin mimics. Clin Dev Immunol 2005, 12:217-224.
22. Smyk D.S., Rigopoulou E.I., Muratori L., Burroughs A.K., Bogdanos D.P. Smoking as a risk factor for autoimmune liver disease: what we can learn from primary biliary cirrhosis. Ann Hepatol 2012, 11:7-14.
23. Israeli E., Agmon-Levin N., Blank M., Shoenfeld Y. Adjuvants and autoimmunity. Lupus 2009, 18:1217-1225.
24. Nancy A.L., Shoenfeld Y. Chronic fatigue syndrome with autoantibodies-the result of an augmented adjuvant effect of hepatitis-B vaccine and silicone implant. Autoimmun Rev 2008, 8:52-55.
25. Perricone C., Agmon-Levin N., Valesini G., Shoenfeld Y. Vaccination in patients with chronic or autoimmune rheumatic diseases: the ego, the id and the superego. Joint Bone Spine 2012, 79:1-3.
26. Rosenblum H., Shoenfeld Y., Amital H. The common immunogenic etiology of chronic fatigue syndrome: from infections to vaccines via adjuvants to the ASIA syndrome. Infect Dis Clin North Am 2011, 25:851-863.
27. Shoenfeld Y., Agmon-Levin N. 'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 2011, 36:4-8.
28. Agmon-Levin N., Hughes G.R., Shoenfeld Y. The spectrum of ASIA: 'Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants'. Lupus 2012, 21:118-120.
29. Katzav A., Kivity S., Blank M., Shoenfeld Y., Chapman J. Adjuvant immunization induces high levels of pathogenic antiphospholipid antibodies in genetically prone mice: another facet of the ASIA syndrome. Lupus 2012, 21:210-216.
30. Kivity S., Katz M., Langevitz P., Eshed I., Olchovski D., Barzilai A. Autoimmune syndrome induced by adjuvants (ASIA) in the Middle East: morphea following silicone implantation. Lupus 2012, 21:136-139.
31. Zafrir Y., Agmon-Levin N., Paz Z., Shilton T., Shoenfeld Y. Autoimmunity following hepatitis B vaccine as part of the spectrum of 'Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants' (ASIA): analysis of 93 cases. Lupus 2012, 21:146-152.
32. Blank M., Israeli E., Shoenfeld Y. When APS (Hughes syndrome) met the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). Lupus 2012, 21:711-714.
33. Arlt V.M., Schwerdtle T. UKEMS/Dutch EMS-sponsored workshop on biomarkers of exposure and oxidative DNA damage & 7th GUM-32P-postlabelling workshop, University of Munster, Munster, Germany, 28-29 March 2011. Mutagenesis Sep 2011, 26(5):679-685. http://dx.doi.org/10.1093/mutage/ger036 [Electronic publication ahead of print 2011 Jun 21].
34. Pleil J.D., Stiegel M.A., Sobus J.R., Liu Q., Madden M.C. Observing the human exposome as reflected in breath biomarkers: heat map data interpretation for environmental and intelligence research. J Breath Res 2011, 5:037104.
35. Rappaport S.M. Implications of the exposome for exposure science. J Expo Sci Environ Epidemiol 2011, 21:5-9.
36. Wild C.P. Complementing the genome with an "exposome": the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol Biomarkers Prev 2005, 14:1847-1850.
37. Wild C.P. Environmental exposure measurement in cancer epidemiology. Mutagenesis 2009, 24:117-125.
38. Smith M.T., Zhang L., McHale C.M., Skibola C.F., Rappaport S.M. Benzene, the exposome and future investigations of leukemia etiology. Chem Biol Interact 2011, 192:155-159.
39. Collin M., Shannon O., Bjorck L. IgG glycan hydrolysis by a bacterial enzyme as a therapy against autoimmune conditions. Proc Natl Acad Sci U S A 2008, 105:4265-4270.
40. Allhorn M., Olin A.I., Nimmerjahn F., Collin M. Human IgG/Fc gamma R interactions are modulated by streptococcal IgG glycan hydrolysis. PLoS One 2008, 3:e1413.
41. McCulloch J., Zhang Y.W., Dawson M., Harkiss G.D., Peterhans E., Vogt H.R., et al. Glycosylation of IgG during potentially arthritogenic lentiviral infections. Rheumatol Int 1995, 14:243-248.
42. Polacco B.J., Purvine S.O., Zink E.M., Lavoie S.P., Lipton M.S., Summers A.O., et al. Discovering mercury protein modifications in whole proteomes using natural isotope distributions observed in liquid chromatography-tandem mass spectrometry. Molecular & cellular proteomics. Mol Cell Proteomics 2011 Aug, 10(8). [M110.004853].
43. McLaren Howard J. The detection of DNA adducts (risk factors for DNA damage). A method for genomic DNA, the results and some effects of nutritional intervention. J Nutr Environ Med 2002, 12:19-31.
44. Patel C.J., Bhattacharya J., Butte A.J. An Environment-Wide Association Study (EWAS) on type 2 diabetes mellitus. PLoS One 2010, 5:e10746.
45. Karges W., Hammond-McKibben D., Cheung R.K., Visconti M., Shibuya N., Kemp D., et al. Immunological aspects of nutritional diabetes prevention in NOD mice: a pilot study for the cow's milk-based IDDM prevention trial. Diabetes 1997, 46:557-564.
46. Guggenmos J., Schubart A.S., Ogg S., Andersson M., Olsson T., Mather I.H., et al. Antibody cross-reactivity between myelin oligodendrocyte glycoprotein and the milk protein butyrophilin in multiple sclerosis. J Immunol 2004, 172:661-668.
47. Molina V., Shoenfeld Y. Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity 2005, 38:235-245.
48. Pordeus V., Szyper-Kravitz M., Levy R.A., Vaz N.M., Shoenfeld Y. Infections and autoimmunity: a panorama. Clin Rev Allergy Immunol 2008, 34:283-299.
49. Doria A., Sarzi-Puttini P., Shoenfeld Y. Infections, rheumatism and autoimmunity: the conflicting relationship between humans and their environment. Autoimmun Rev 2008, 8:1-4.
50. Tozzoli R., Barzilai O., Ram M., Villalta D., Bizzaro N., Sherer Y., et al. Infections and autoimmune thyroid diseases: parallel detection of antibodies against pathogens with proteomic technology. Autoimmun Rev 2008, 8:112-115.
51. Corthesy B. Role of secretory IgA in infection and maintenance of homeostasis. Autoimmun Rev Nov 29 2012, http://dx.doi.org/10.1016/j.autrev.2012.10.012 [pii: S1568-9972(12)00270-4. Electronic publication ahead of print PMID: 23201924].
52. Brown J.M., Pfau J.C., Pershouse M.A., Holian A. Silica, apoptosis, and autoimmunity. J Immunotoxicol 2005, 1:177-187.
53. Otsuki T., Hayashi H., Nishimura Y., Hyodo F., Maeda M., Kumagai N., et al. Dysregulation of autoimmunity caused by silica exposure and alteration of Fas-mediated apoptosis in T lymphocytes derived from silicosis patients. Int J Immunopathol Pharmacol 2011, 24:11S-16S.
54. Cooper G.S., Wither J., Bernatsky S., Claudio J.O., Clarke A., Rioux J.D., et al. Occupational and environmental exposures and risk of systemic lupus erythematosus: silica, sunlight, solvents. Rheumatology 2010, 49:2172-2180.
55. Finckh A., Cooper G.S., Chibnik L.B., Costenbader K.H., Watts J., Pankey H., et al. Occupational silica and solvent exposures and risk of systemic lupus erythematosus in urban women. Arthritis Rheum 2006, 54:3648-3654.
56. Parks C.G., Cooper G.S. Occupational exposures and risk of systemic lupus erythematosus: a review of the evidence and exposure assessment methods in population- and clinic-based studies. Lupus 2006, 15:728-736.
57. Griffin J.M., Gilbert K.M., Lamps L.W., Pumford N.R. CD4(+) T-cell activation and induction of autoimmune hepatitis following trichloroethylene treatment in MRL+/+ mice. Toxicol Sci 2000, 57:345-352.
58. Khan M.F., Kaphalia B.S., Prabhakar B.S., Kanz M.F., Ansari G.A. Trichloroethene-induced autoimmune response in female MRL +/+ mice. Toxicol Appl Pharmacol 1995, 134:155-160.
59. Duntas L.H. Environmental factors and thyroid autoimmunity. Ann Endocrinol (Paris) 2011, 72:108-113.
60. Parks C.G., Walitt B.T., Pettinger M., Chen J.C., de Roos A.J., Hunt J., et al. Insecticide use and risk of rheumatoid arthritis and systemic lupus erythematosus in the Women's Health Initiative Observational Study. Arthritis Care Res (Hoboken) 2011, 63:184-194.
61. Fortes C. Lupus erythematosus. Are residential insecticides exposure the missing link?. Med Hypotheses 2010, 75:590-593.
62. Burek C.L., Talor M.V. Environmental triggers of autoimmune thyroiditis. J Autoimmun 2009, 33:183-189.
63. Gold L.S., Ward M.H., Dosemeci M., De Roos A.J. Systemic autoimmune disease mortality and occupational exposures. Arthritis Rheum 2007, 56:3189-3201.
64. Sobel E.S., Gianini J., Butfiloski E.J., Croker B.P., Schiffenbauer J., Roberts S.M. Acceleration of autoimmunity by organochlorine pesticides in (NZB×NZW)F1 mice. Environ Health Perspect 2005, 113:323-328.
65. Mayes M.D. Epidemiologic studies of environmental agents and systemic autoimmune diseases. Environ Health Perspect 1999, 107(Suppl. 5):743-748.
66. Artukovic M., Ikic M., Kustelega J., Artukovic I.N., Kaliterna D.M. Influence of UV radiation on immunological system and occurrence of autoimmune diseases. Coll Antropol 2010, 34(Suppl. 2):175-178.
67. Handunnetthi L., Ramagopalan S.V. UV radiation, vitamin D, and multiple sclerosis. Proc Natl Acad Sci U S A 2010, 107:E130. [author reply E1].
68. Prieto S., Grau J.M. The geoepidemiology of autoimmune muscle disease. Autoimmun Rev 2010, 9:A330-A334.
69. Kuhn A., Beissert S. Photosensitivity in lupus erythematosus. Autoimmunity 2005, 38:519-529.
70. Tumgor G., Balkan C., Arikan C., Kavakli K., Aydogdu S. Immune haemolytic anaemia induced by allopurinol after liver transplantation. Acta Paediatr 2006, 95:762-763.
71. Pujol M., Duran-Suarez J.R., Martin Vega C., Sanchez C., Tovar J.L., Valles M. Autoimmune thrombocytopenia in three patients treated with captopril. Vox Sang 1989, 57:218.
72. Gharavi A.E., Sammaritano L.R., Wen J., Miyawaki N., Morse J.H., Zarrabi M.H., et al. Characteristics of human immunodeficiency virus and chlorpromazine induced antiphospholipid antibodies: effect of beta 2 glycoprotein I on binding to phospholipid. J Rheumatol 1994, 21:94-99.
73. Canoso R.T., de Oliveira R.M. Chlorpromazine-induced anticardiolipin antibodies and lupus anticoagulant: absence of thrombosis. Am J Hematol 1988, 27:272-275.
74. Stein P.B., Inwood M.J. Hemolytic anemia associated with chlorpromazine therapy. Can J Psychiatry 1980, 25:659-661.
75. Hadnagy C. Letter: Coombs-positive haemolytic anaemia provoked by chlorpromazine. Lancet 1976, 1:423.
76. Berglund S., Gottfries C.G., Gottfries I., Stormby K. Chlorpromazine-induced antinuclear factors. Acta Med Scand 1970, 187:67-74.
77. Liu Z.X., Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002, 6:755-774.
78. Yung R.L., Richardson B.C. Drug-induced lupus. Rheum Dis Clin North Am 1994, 20:61-86.
79. Czaja A.J. Drug-induced autoimmune-like hepatitis. Dig Dis Sci 2011, 56:958-976.
80. Chighizola C., Meroni P.L. The role of environmental estrogens and autoimmunity. Autoimmun Rev 2012, 11:A493-A501.
81. Shapira Y., Agmon-Levin N., Renaudineau Y., Porat-Katz B.S., Barzilai O., Ram M., et al. Serum markers of infections in patients with primary biliary cirrhosis: evidence of infection burden. Exp Mol Pathol 2012, 93:386-390.
82. Shapira Y., Agmon-Levin N., Shoenfeld Y. Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun 2010, 34:J168-J177.
83. Berlin T., Zandman-Goddard G., Blank M., Matthias T., Pfeiffer S., Weis I., et al. Autoantibodies in nonautoimmune individuals during infections. Ann N Y Acad Sci 2007, 1108:584-593.
84. Saad R., Rizkallah M.R., Aziz R.K. Gut pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes. Gut Pathog 2012, 4:16.
85. Buccigrossi V., Nicastro E., Guarino A. Functions of intestinal microflora in children. Curr Opin Gastroenterol 2013, 29:31-38.
86. Gielda L.M., DiRita V.J. Zinc competition among the intestinal microbiota. MBio 2012, 3:e00171-e.
87. Lidar M., Agmon-Levin N., Langevitz P., Shoenfeld Y. Silicone and scleroderma revisited. Lupus 2012, 21:121-127.
88. Shoenfeld Y., Toubi E. Protective autoantibodies: role in homeostasis, clinical importance, and therapeutic potential. Arthritis Rheum 2005, 52:2599-2606.
89. Toubi E., Shoenfeld Y. Predictive and protective autoimmunity in cardiovascular diseases: is vaccination therapy a reality?. Lupus 2005, 14:665-669.
90. Ram M., Anaya J.M., Barzilai O., Izhaky D., Porat Katz B.S., Blank M., et al. The putative protective role of hepatitis B virus (HBV) infection from autoimmune disorders. Autoimmun Rev 2008, 7:621-625.
91. Meroni P.L., Shoenfeld Y. Predictive, protective, orphan autoantibodies: the example of anti-phospholipid antibodies. Autoimmun Rev 2008, 7:585-587.
92. Plot L., Amital H., Barzilai O., Ram M., Nicola B., Shoenfeld Y. Infections may have a protective role in the etiopathogenesis of celiac disease. Ann N Y Acad Sci 2009, 1173:670-674.
93. Guilherme L., Oshiro S.E., Fae K.C., Cunha-Neto E., Renesto G., Goldberg A.C., et al. T-cell reactivity against streptococcal antigens in the periphery mirrors reactivity of heart-infiltrating T lymphocytes in rheumatic heart disease patients. Infect Immun 2001, 69:5345-5351.
94. Amedei A., Bergman M.P., Appelmelk B.J., Azzurri A., Benagiano M., Tamburini C., et al. Molecular mimicry between Helicobacter pylori antigens and H+, K+-adenosine triphosphatase in human gastric autoimmunity. J Exp Med 2003, 198:1147-1156.
95. Cunha-Neto E., Coelho V., Guilherme L., Fiorelli A., Stolf N., Kalil J. Autoimmunity in Chagas' disease. Identification of cardiac myosin-B13 Trypanosoma cruzi protein crossreactive T cell clones in heart lesions of a chronic Chagas' cardiomyopathy patient. J Clin Invest 1996, 98:1709-1712.
96. da Rocha Sobrinho H.M., Jarach R., da Silva N.A., Shio M.T., Jancar S., Timenetsky J., et al. Mycoplasmal lipid-associated membrane proteins and Mycoplasma arthritidis mitogen recognition by serum antibodies from patients with rheumatoid arthritis. Rheumatol Int 2011, 31:951-957.
97. Tobon G.J., Pers J.O., Canas C.A., Rojas-Villarraga A., Youinou P., Anaya J.M. Are autoimmune diseases predictable?. Autoimmun Rev 2012, 11:259-266.
98. Jones D.E. Pathogenesis of primary biliary cirrhosis. Gut 2007, 56:1615-1624.
99. Kaplan M.M., Gershwin M.E. Primary biliary cirrhosis. N Engl J Med 2005, 353:1261-1273.
100. Arbuckle M.R., McClain M.T., Rubertone M.V., Scofield R.H., Dennis G.J., James J.A., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349:1526-1533.
101. Harley J.B., Harley I.T., Guthridge J.M., James J.A. The curiously suspicious: a role for Epstein-Barr virus in lupus. Lupus 2006, 15:768-777.
102. Harley J.B., James J.A. Epstein-Barr virus infection induces lupus autoimmunity. Bull NYU Hosp Jt Dis 2006, 64:45-50.
103. Navarra S.V., Ishimori M.I., Uy E.A., Hamijoyo L., Sama J., James J.A., et al. Studies of Filipino patients with systemic lupus erythematosus: autoantibody profile of first-degree relatives. Lupus 2011, 20:537-543.
104. Zandman-Goddard G., Berkun Y., Barzilai O., Boaz M., Blank M., Ram M., et al. Exposure to Epstein-Barr virus infection is associated with mild systemic lupus erythematosus disease. Ann N Y Acad Sci 2009, 1173:658-663.
105. Barzilai O., Sherer Y., Ram M., Izhaky D., Anaya J.M., Shoenfeld Y. Epstein-Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious? A preliminary report. Ann N Y Acad Sci 2007, 1108:567-577.
106. Bengtsson A., Widell A., Elmstahl S., Sturfelt G. No serological indications that systemic lupus erythematosus is linked with exposure to human parvovirus B19. Ann Rheum Dis 2000, 59:64-66.
107. Hemauer A., Beckenlehner K., Wolf H., Lang B., Modrow S. Acute parvovirus B19 infection in connection with a flare of systemic lupus erythematodes in a female patient. J Clin Virol 1999, 14:73-77.
108. Hrycek A., Kusmierz D., Mazurek U., Wilczok T. Human cytomegalovirus in patients with systemic lupus erythematosus. Autoimmunity 2005, 38:487-491.
109. James J.A., Neas B.R., Moser K.L., Hall T., Bruner G.R., Sestak A.L., et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum 2001, 44:1122-1126.
110. Seishima M., Oyama Z., Yamamura M. Two-year follow-up study after human parvovirus B19 infection. Dermatology 2003, 206:192-196.
111. Parks C.G., Cooper G.S., Hudson L.L., Dooley M.A., Treadwell E.L., St Clair E.W., et al. Association of Epstein-Barr virus with systemic lupus erythematosus: effect modification by race, age, and cytotoxic T lymphocyte-associated antigen 4 genotype. Arthritis Rheum 2005, 52:1148-1159.
112. Wang H., Nicholas M.W., Conway K.L., Sen P., Diz R., Tisch R.M., et al. EBV latent membrane protein 2A induces autoreactive B cell activation and TLR hypersensitivity. J Immunol 2006, 177:2793-2802.
113. Chang M., Pan M.R., Chen D.Y., Lan J.L. Human cytomegalovirus pp 65 lower matrix protein: a humoral immunogen for systemic lupus erythematosus patients and autoantibody accelerator for NZB/W F1 mice. Clin Exp Immunol 2006, 143:167-179.
114. Gilden D.H. Infectious causes of multiple sclerosis. Lancet Neurol 2005, 4:195-202.
115. Kakalacheva K., Lunemann J.D. Environmental triggers of multiple sclerosis. FEBS Lett 2011, 23:3724-3729. [PMID: 21486562].
116. Hammond S.R., English D.R., McLeod J.G. The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia. Brain 2000, 123(Pt 5):968-974.
117. Kurtzke J.F., Delasnerie-Laupretre N., Wallin M.T. Multiple sclerosis in North African migrants to France. Acta Neurol Scand 1998, 98:302-309.
118. Kurtzke J.F., Hyllested K. Multiple sclerosis in the Faroe Islands: I. Clinical and epidemiological features. Ann Neurol 1979, 5:6-21.
119. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. N Engl J Med 2000, 343:938-952.
120. Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 2006, 354:942-955.
121. Giovannoni G., Cutter G.R., Lunemann J., Martin R., Munz C., Sriram S., et al. Infectious causes of multiple sclerosis. Lancet Neurol 2006, 5:887-894.
122. Giovannoni G., Ebers G. Multiple sclerosis: the environment and causation. Curr Opin Neurol 2007, 20:261-268.
123. Ebers G.C., Sadovnick A.D., Risch N.J. A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature 1995, 377:150-151.
124. Sadovnick A.D., Ebers G.C., Dyment D.A., Risch N.J. Evidence for genetic basis of multiple sclerosis. The Canadian Collaborative Study Group. Lancet 1996, 347:1728-1730.
125. Barcellos L.F., Sawcer S., Ramsay P.P., Baranzini S.E., Thomson G., Briggs F., et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet 2006, 15:2813-2824.
126. Hafler D.A., Compston A., Sawcer S., Lander E.S., Daly M.J., De Jager P.L., et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007, 357:851-862.
127. Qu H.Q., Bradfield J.P., Belisle A., Grant S.F., Hakonarson H., Polychronakos C. The type I diabetes association of the IL2RA locus. Genes Immun 2009, 10(Suppl. 1):S42-S48.
128. Arnson Y., Amital H., Shoenfeld Y. Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis 2007, 66:1137-1142.
129. Carvalho J.F., Blank M., Kiss E., Tarr T., Amital H., Shoenfeld Y. Anti-vitamin D, vitamin D in SLE: preliminary results. Ann N Y Acad Sci 2007, 1109:550-557.
130. Shoenfeld N., Amital H., Shoenfeld Y. The effect of melanism and vitamin D synthesis on the incidence of autoimmune disease. Nat Clin Pract Rheumatol 2009, 5:99-105.
131. Shapira Y., Agmon-Levin N., Shoenfeld Y. Mycobacterium tuberculosis, autoimmunity, and vitamin D. Clin Rev Allergy Immunol 2010, 38:169-177.
132. Amital H., Szekanecz Z., Szucs G., Danko K., Nagy E., Csepany T., et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D?. Ann Rheum Dis 2010, 69:1155-1157.
133. Toubi E., Shoenfeld Y. The role of vitamin D in regulating immune responses. Isr Med Assoc J 2010, 12:174-175.
134. Souberbielle J.C., Body J.J., Lappe J.M., Plebani M., Shoenfeld Y., Wang T.J., et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice. Autoimmun Rev 2010, 9:709-715.
135. Agmon-Levin N., Blank M., Zandman-Goddard G., Orbach H., Meroni P.L., Tincani A., et al. Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis 2011, 70:145-150.
136. Oren Y., Shapira Y., Agmon-Levin N., Kivity S., Zafrir Y., Altman A., et al. Vitamin D insufficiency in a sunny environment: a demographic and seasonal analysis. Isr Med Assoc J 2010, 12:751-756.
137. Kivity S., Agmon-Levin N., Zisappl M., Shapira Y., Nagy E.V., Danko K., et al. Vitamin D and autoimmune thyroid diseases. Cell Mol Immunol 2011, 8:243-247.
138. Lerner A., Shapira Y., Agmon-Levin N., Pacht A., Ben-Ami Shor D., Lopez H.M., et al. The clinical significance of 25OH-Vitamin D status in celiac disease. Clin Rev Allergy Immunol 2012, 42:322-330.
139. Hajas A., Sandor J., Csathy L., Csipo I., Barath S., Paragh G., et al. Vitamin D insufficiency in a large MCTD population. Autoimmun Rev 2011, 10:317-324.
140. Cutolo M., Pizzorni C., Sulli A. Vitamin D endocrine system involvement in autoimmune rheumatic diseases. Autoimmun Rev 2011, 11:84-87.
141. Lucas R.M., Ponsonby A.L., Dear K., Valery P.C., Pender M.P., Taylor B.V., et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 2011, 76:540-548.
142. Munger K.L., Levin L.I., Hollis B.W., Howard N.S., Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296:2832-2838.
143. Handel A.E., Williamson A.J., Disanto G., Dobson R., Giovannoni G., Ramagopalan S.V. Smoking and multiple sclerosis: an updated meta-analysis. PLoS One 2011, 6:e16149.
144. Hedstrom A.K., Sundqvist E., Baarnhielm M., Nordin N., Hillert J., Kockum I., et al. Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis. Brain 2011, 134:653-664.
145. Stejskal V., Hudecek R., Stejskal J., Sterzl I. Diagnosis and treatment of metal-induced side-effects. Neuro Endocrinol Lett 2006, 27(Suppl. 1):7-16.
146. Fleming J.O. Helminths and multiple sclerosis: will old friends give us new treatments for MS?. J Neuroimmunol 2011, 233:3-5.
147. Gaisford W., Cooke A. Can infections protect against autoimmunity?. Curr Opin Rheumatol 2009, 21:391-396.
148. Albright A.V., Lavi E., Black J.B., Goldberg S., O'Connor M.J., Gonzalez-Scarano F. The effect of human herpesvirus-6 (HHV-6) on cultured human neural cells: oligodendrocytes and microglia. J Neurovirol 1998, 4:486-494.
149. Chan P.K., Ng H.K., Cheng A.F. Detection of human herpesviruses 6 and 7 genomic sequences in brain tumours. J Clin Pathol 1999, 52:620-623.
150. Kim J.S., Lee K.S., Park J.H., Kim M.Y., Shin W.S. Detection of human herpesvirus 6 variant A in peripheral blood mononuclear cells from multiple sclerosis patients. Eur Neurol 2000, 43:170-173.
151. Opsahl M.L., Kennedy P.G. Early and late HHV-6 gene transcripts in multiple sclerosis lesions and normal appearing white matter. Brain 2005, 128:516-527.
152. Mirandola P., Stefan A., Brambilla E., Campadelli-Fiume G., Grimaldi L.M. Absence of human herpesvirus 6 and 7 from spinal fluid and serum of multiple sclerosis patients. Neurology 1999, 53:1367-1368.
153. Sospedra M., Zhao Y., zur Hausen H., Muraro P.A., Hamashin C., de Villiers E.M., et al. Recognition of conserved amino acid motifs of common viruses and its role in autoimmunity. PLoS Pathog 2005, 1:e41.
154. Bogdanos D.P., Gershwin M.E. What is new in primary biliary cirrhosis?. Dig Dis 2012, 30(Suppl. 1):20-31.
155. Corpechot C., Chretien Y., Chazouilleres O., Poupon R. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol 2010, 53:162-169.
156. Gershwin M.E., Selmi C., Worman H.J., Gold E.B., Watnik M., Utts J., et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005, 42:1194-1202.
157. Parikh-Patel A., Gold E.B., Worman H., Krivy K.E., Gershwin M.E. Risk factors for primary biliary cirrhosis in a cohort of patients from the united states. Hepatology 2001, 33:16-21.
158. Prince M.I., Ducker S.J., James O.F. Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations. Gut 2010, 59:508-512.
159. Invernizzi P., Selmi C., Gershwin M.E. Update on primary biliary cirrhosis. Dig Liver Dis 2010, 42:401-408.
160. Selmi C., Invernizzi P., Zuin M., Podda M., Gershwin M.E. Genetics and geoepidemiology of primary biliary cirrhosis: following the footprints to disease etiology. Semin Liver Dis 2005, 25:265-280.
161. Selmi C., Invernizzi P., Zuin M., Podda M., Seldin M.F., Gershwin M.E. Genes and (auto)immunity in primary biliary cirrhosis. Genes Immun 2005, 6:543-556.
162. Smyk D., Cholongitas E., Kriese S., Rigopoulou E.I., Bogdanos D.P. Primary biliary cirrhosis: family stories. Autoimmune Dis 2011, 2011:189585.
163. Bogdanos D.P., Smyk D.S., Rigopoulou E.I., Mytilinaiou M.G., Heneghan M.A., Selmi C., et al. Twin studies in autoimmune disease: genetics, gender and environment. J Autoimmun 2012, 38:J156-J169.
164. Gershwin M.E., Mackay I.R. The causes of primary biliary cirrhosis: convenient and inconvenient truths. Hepatology 2008, 47:737-745.
165. Konikoff F., Pecht M., Theodor E., Shoenfeld Y. Primary biliary cirrhosis: lymphocyte subsets and function in a time frame. Hepatology 1989, 10:525-526.
166. Schlesinger M., Benbassat C., Shoenfeld Y. Complement profile in primary biliary cirrhosis. Immunol Res 1992, 11:98-103.
167. Shoenfeld Y. Primary biliary cirrhosis and autoimmune rheumatic diseases: prediction and prevention. Isr J Med Sci 1992, 28:113-116.
168. Weiss P., Shoenfeld Y. Primary biliary cirrhosis is a multisystem disorder. Ann Med Interne (Paris) 1991, 142:283-287.
169. Weiss P., Shoenfeld Y. Primary biliary cirrhosis: increasing problem, approaching solution. Isr J Med Sci 1992, 28:726-728.
170. Benbassat C., Schlesinger M., Shoenfeld Y. The complement system and primary biliary cirrhosis. J Clin Lab Immunol 1992, 38:51-61.
171. Rotman P., Levy Y., Shoenfeld Y. Primary biliary cirrhosis-association or overlap with other autoimmune diseases. Isr J Med Sci 1997, 33:823-825.
172. Shapira S., Bar-Dayan Y., Gershwin M.E., Shoenfeld Y. Is it possible to predict and prevent primary biliary cirrhosis?. Harefuah 1999, 137:39-41.
173. Aoki C.A., Roifman C.M., Lian Z.X., Bowlus C.L., Norman G.L., Shoenfeld Y., et al. IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. J Autoimmun 2006, 27:50-53.
174. Barak V., Selmi C., Schlesinger M., Blank M., Agmon-Levin N., Kalickman I., et al. Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis. J Autoimmun 2009, 33:178-182.
175. Bogdanos D.P., Baum H., Vergani D. Antimitochondrial and other autoantibodies. Clin Liver Dis 2003, 7:759-777. [vi].
176. Bogdanos D.P., Baum H., Vergani D., Burroughs A.K. The role of E. coli infection in the pathogenesis of primary biliary cirrhosis. Dis Markers 2010, 29:301-311.
177. Bogdanos D.P., Vergani D. Origin of cross-reactive autoimmunity in primary biliary cirrhosis. Liver Int 2006, 26:633-635.
178. Bogdanos D.P., Vergani D. Bacteria and primary biliary cirrhosis. Clin Rev Allergy Immunol 2009, 36:30-39.
179. Gershwin M.E., Mackay I.R. Primary biliary cirrhosis: paradigm or paradox for autoimmunity. Gastroenterology 1991, 100:822-833.
180. Mackay I.R., Whittingham S., Fida S., Myers M., Ikuno N., Gershwin M.E., et al. The peculiar autoimmunity of primary biliary cirrhosis. Immunol Rev 2000, 174:226-237.
181. Shimoda S., Nakamura M., Ishibashi H., Hayashida K., Niho Y. HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases. J Exp Med 1995, 181:1835-1845.
182. Shimoda S., Nakamura M., Shigematsu H., Tanimoto H., Gushima T., Gershwin M.E., et al. Mimicry peptides of human PDC-E2 163-176 peptide, the immunodominant T-cell epitope of primary biliary cirrhosis. Hepatology 2000, 31:1212-1216.
183. Shimoda S., Van de Water J., Ansari A., Nakamura M., Ishibashi H., Coppel R.L., et al. Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J Clin Invest 1998, 102:1831-1840.
184. Vergani D., Bogdanos D.P. Positive markers in AMA-negative PBC. Am J Gastroenterol 2003, 98:241-243.
185. Hohenester S., Oude-Elferink R.P., Beuers U. Primary biliary cirrhosis. Semin Immunopathol 2009, 31:283-307.
186. Neuberger J. Primary biliary cirrhosis. Lancet 1997, 350:875-879.
187. Bogdanos D.P., Invernizzi P., Mackay I.R., Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol 2008, 14:3374-3387.
188. Bogdanos D.P., Komorowski L. Disease-specific autoantibodies in primary biliary cirrhosis. Clin Chim Acta 2011, 412:502-512.
189. Dahnrich C., Pares A., Caballeria L., Rosemann A., Schlumberger W., Probst C., et al. New ELISA for detecting primary biliary cirrhosis-specific antimitochondrial antibodies. Clin Chem 2009, 55:978-985.
190. Liu H., Norman G.L., Shums Z., Worman H.J., Krawitt E.L., Bizzaro N., et al. PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun 2010, 35:436-442.
191. Ma Y., Thomas M.G., Okamoto M., Bogdanos D.P., Nagl S., Kerkar N., et al. Key residues of a major cytochrome P4502D6 epitope are located on the surface of the molecule. J Immunol 2002, 169:277-285.
192. Rigopoulou E.I., Davies E.T., Bogdanos D.P., Liaskos C., Mytilinaiou M., Koukoulis G.K., et al. Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis. Liver Int 2007, 27:1226-1231.
193. Wen L., Ma Y., Bogdanos D.P., Wong F.S., Demaine A., Mieli-Vergani G., et al. Pediatric autoimmune liver diseases: the molecular basis of humoral and cellular immunity. Curr Mol Med 2001, 1:379-389.
194. Invernizzi P., Lleo A., Podda M. Interpreting serological tests in diagnosing autoimmune liver diseases. Semin Liver Dis 2007, 27:161-172.
195. Rigopoulou E.I., Bogdanos D.P., Liaskos C., Koutsoumpas A., Baum H., Vergani D., et al. Anti-mitochondrial antibody immunofluorescent titres correlate with the number and intensity of immunoblot-detected mitochondrial bands in patients with primary biliary cirrhosis. Clin Chim Acta 2007, 380:118-121.
196. Gilburd B., Ziporen L., Zharhary D., Blank M., Zurgil N., Scheinberg M.A., et al. Antimitochondrial (pyruvate dehydrogenase) antibodies in leprosy. J Clin Immunol 1994, 14:14-19.
197. Konikoff F., Isenberg D.A., Barrison I., Theodor E., Shoenfeld Y. Antinuclear autoantibodies in chronic liver diseases. Hepatogastroenterology 1989, 36:341-345.
198. Konikoff F., Isenberg D.A., Kooperman O., Kennedy R.C., Rauch J., Theodor E., et al. Common lupus anti-DNA antibody idiotypes in chronic liver diseases. Clin Immunol Immunopathol 1987, 43:265-272.
199. Konikoff F., Shoenfeld Y., Isenberg D.A., Barrison I., Sobe T., Theodor E., et al. Anti-Rnp antibodies in chronic liver diseases. Clin Exp Rheumatol 1987, 5:359-361.
200. Krause I., Hacham S., Gilburd B., Damianovitch M., Blank M., Shoenfeld Y. Absence of anti-idiotypic antibodies in IVIG preparations to autoantibodies of rare autoimmune diseases. Clin Immunol Immunopathol 1995, 77:229-235.
201. Lorber M., Kra-Oz Z., Guilbrud B., Shoenfeld Y. Natural (antiphospholipid-PDH,-DNA) autoantibodies and their physiologic serum inhibitors. Isr J Med Sci 1995, 31:31-35.
202. Maran R., Dueymes M., Adler Y., Shoenfeld Y., Youinou P. Isotypic distribution of anti-pyruvate dehydrogenase antibodies in patients with primary biliary cirrhosis and their family members. J Clin Immunol 1994, 14:323-326.
203. Shoenfeld Y., Beresovski A., Zharhary D., Tomer Y., Swissa M., Sela E., et al. Natural autoantibodies in sera of patients with Gaucher's disease. J Clin Immunol 1995, 15:363-372.
204. Zurgil N., Bakimer R., Kaplan M., Youinou P., Shoenfeld Y. Anti-pyruvate dehydrogenase autoantibodies in primary biliary cirrhosis. J Clin Immunol 1991, 11:239-245.
205. Zurgil N., Bakimer R., Moutsopoulos H.M., Tzioufas A.G., Youinou P., Isenberg D.A., et al. Antimitochondrial (pyruvate dehydrogenase) autoantibodies in autoimmune rheumatic diseases. J Clin Immunol 1992, 12:201-209.
206. Zurgil N., Bakimer R., Slor H., Kaplan M., Moutsopoulos H., Shoenfeld Y. Pyruvate dehydrogenase as an antigen to detect antimitochondrial antibodies. Isr J Med Sci 1990, 26:682-685.
207. Zurgil N., Konikoff F., Bakimer R., Slor H., Shoenfeld Y. Detection of antimitochondrial antibodies: characterization by enzyme immunoassay and immunoblotting. Autoimmunity 1989, 4:289-297.
208. Tishler M., Alosachie I., Barka N., Lin H.C., Gershwin M.E., Peter J.B., et al. Primary Sjogren's syndrome and primary biliary cirrhosis: differences and similarities in the autoantibody profile. Clin Exp Rheumatol 1995, 13:497-500.
209. Bean P., Sutphin M.S., Liu Y., Anton R., Reynolds T.B., Shoenfeld Y., et al. Carbohydrate-deficient transferrin and false-positive results for alcohol abuse in primary biliary cirrhosis: differential diagnosis by detection of mitochondrial autoantibodies. Clin Chem 1995, 41:858-861.
210. Agmon-Levin N., Shapira Y., Selmi C., Barzilai O., Ram M., Szyper-Kravitz M., et al. A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis. J Autoimmun 2010, 34:55-58.
211. Metcalf J.V., Mitchison H.C., Palmer J.M., Jones D.E., Bassendine M.F., James O.F. Natural history of early primary biliary cirrhosis. Lancet 1996, 348:1399-1402.
212. Dubel L., Tanaka A., Leung P.S., Van de Water J., Coppel R., Roche T., et al. Autoepitope mapping and reactivity of autoantibodies to the dihydrolipoamide dehydrogenase-binding protein (E3BP) and the glycine cleavage proteins in primary biliary cirrhosis. Hepatology 1999, 29:1013-1018.
213. Leung P.S., Coppel R.L., Ansari A., Munoz S., Gershwin M.E. Antimitochondrial antibodies in primary biliary cirrhosis. Semin Liver Dis 1997, 17:61-69.
214. Palmer J.M., Jones D.E., Quinn J., McHugh A., Yeaman S.J. Characterization of the autoantibody responses to recombinant E3 binding protein (protein X) of pyruvate dehydrogenase in primary biliary cirrhosis. Hepatology 1999, 30:21-26.
215. Van de Water J., Fregeau D., Davis P., Ansari A., Danner D., Leung P., et al. Autoantibodies of primary biliary cirrhosis recognize dihydrolipoamide acetyltransferase and inhibit enzyme function. J Immunol 1988, 141:2321-2324.
216. Bogdanos D.P., Liaskos C., Pares A., Norman G., Rigopoulou E.I., Caballeria L., et al. Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. Hepatology 2007, 45:1583. [author reply -4].
217. Invernizzi P., Podda M., Battezzati P.M., Crosignani A., Zuin M., Hitchman E., et al. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol 2001, 34:366-372.
218. Miyachi K., Hankins R.W., Matsushima H., Kikuchi F., Inomata T., Horigome T., et al. Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study. J Autoimmun 2003, 20:247-254.
219. Nakamura M., Kondo H., Mori T., Komori A., Matsuyama M., Ito M., et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007, 45:118-127.
220. Rigopoulou E.I., Davies E.T., Pares A., Zachou K., Liaskos C., Bogdanos D.P., et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut 2005, 54:528-532.
221. Itoh S., Ichida T., Yoshida T., Hayakawa A., Uchida M., Tashiro-Itoh T., et al. Autoantibodies against a 210kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. J Gastroenterol Hepatol 1998, 13:257-265.
222. Lassoued K., Guilly M.N., Andre C., Paintrand M., Dhumeaux D., Danon F., et al. Autoantibodies to 200kD polypeptide(s) of the nuclear envelope: a new serologic marker of primary biliary cirrhosis. Clin Exp Immunol 1988, 74:283-288.
223. Muratori P., Muratori L., Ferrari R., Cassani F., Bianchi G., Lenzi M., et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 2003, 98:431-437.
224. Wesierska-Gadek J., Penner E., Battezzati P.M., Selmi C., Zuin M., Hitchman E., et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 2006, 43:1135-1144.
225. Yang W.H., Yu J.H., Nakajima A., Neuberg D., Lindor K., Bloch D.B. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?. Clin Gastroenterol Hepatol 2004, 2:1116-1122.
226. Duarte-Rey C., Bogdanos D., Yang C.Y., Roberts K., Leung P.S., Anaya J.M., et al. Primary biliary cirrhosis and the nuclear pore complex. Autoimmun Rev 2012, 11:898-902.
227. Duarte-Rey C., Bogdanos D.P., Leung P.S., Anaya J.M., Gershwin M.E. IgM predominance in autoimmune disease: genetics and gender. Autoimmun Rev 2012, 11:A404-A412.
228. Bach N., Schaffner F. Familial primary biliary cirrhosis. J Hepatol 1994, 20:698-701.
229. Floreani A., Naccarato R., Chiaramonte M. Prevalence of familial disease in primary biliary cirrhosis in Italy. J Hepatol 1997, 26:737-738.
230. Tsuji K., Watanabe Y., Van De Water J., Nakanishi T., Kajiyama G., Parikh-Patel A., et al. Familial primary biliary cirrhosis in Hiroshima. J Autoimmun 1999, 13:171-178.
231. Lazaridis K.N., Juran B.D., Boe G.M., Slusser J.P., de Andrade M., Homburger H.A., et al. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology 2007, 46:785-792.
232. Douglas J.G., Finlayson N.D. Are increased individual susceptibility and environmental factors both necessary for the development of primary biliary cirrhosis?. BMJ 1979, 2:419-420.
233. Fagan E., Williams R., Cox S. Primary biliary cirrhosis in mother and daughter. BMJ 1977, 2:1195.
234. Tong M.J., Nies K.M., Reynolds T.B., Quismorio F.P. Immunological studies in familial primary biliary cirrhosis. Gastroenterology 1976, 71:305-307.
235. Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol 2010, 52:745-758.
236. Corpechot C., Carrat F., Poupon R., Poupon R.E. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 2002, 122:652-658.
237. Smyk D.S., Rigopoulou E.I., Bogdanos D.P. Potential roles for infectious agents in the pathophysiology of primary biliary cirrhosis: what's new?. Curr Infect Dis Rep Nov 29 2012, [Electronic publication ahead of print].
238. Chuang Y.H., Ridgway W.M., Ueno Y., Gershwin M.E. Animal models of primary biliary cirrhosis. Clin Liver Dis 2008, 12:333-347. [ix].
239. Hirschfield G.M., Invernizzi P. Progress in the genetics of primary biliary cirrhosis. Semin Liver Dis 2011, 31:147-156.
240. Lleo A., Invernizzi P., Mackay I.R., Prince H., Zhong R.Q., Gershwin M.E. Etiopathogenesis of primary biliary cirrhosis. World J Gastroenterol 2008, 14:3328-3337.
241. Selmi C., Zuin M., Gershwin M.E. The unfinished business of primary biliary cirrhosis. J Hepatol 2008, 49:451-460.
242. Wu S.J., Yang Y.H., Tsuneyama K., Leung P.S., Illarionov P., Gershwin M.E., et al. Innate immunity and primary biliary cirrhosis: activated invariant natural killer T cells exacerbate murine autoimmune cholangitis and fibrosis. Hepatology 2011, 53:915-925.
243. Hirschfield G.M., Gershwin M.E. Primary biliary cirrhosis: one disease with many faces. Isr Med Assoc J 2011, 13:55-59.
244. Invernizzi P. Human leukocyte antigen in primary biliary cirrhosis: an old story now reviving. Hepatology 2011, 2:714-723. [PMID: 21563204].
245. Hemminki K., Li X., Sundquist K., Sundquist J. Shared familial aggregation of susceptibility to autoimmune diseases. Arthritis Rheum 2009, 60:2845-2847.
246. Hirschfield G.M., Liu X., Han Y., Gorlov I.P., Lu Y., Xu C., et al. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet 2010, 42:655-657.
247. Hirschfield G.M., Liu X., Xu C., Lu Y., Xie G., Gu X., et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 2009, 360:2544-2555.
248. Liu X., Invernizzi P., Lu Y., Kosoy R., Bianchi I., Podda M., et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet 2010, 42:658-660.
249. Mells G.F., Floyd J.A., Morley K.I., Cordell H.J., Franklin C.S., Shin S.Y., et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet 2011, 43:329-332.
250. Tanaka A., Invernizzi P., Ohira H., Kikuchi K., Nezu S., Kosoy R., et al. Replicated association of 17q12-21 with susceptibility of primary biliary cirrhosis in a Japanese cohort. Tissue Antigens 2011, 78:65-68.
251. Tanaka A., Ohira H., Kikuchi K., Nezu S., Shibuya A., Bianchi I., et al. Genetic association of Fc receptor-like 3 polymorphisms with susceptibility to primary biliary cirrhosis: ethnic comparative study in Japanese and Italian patients. Tissue Antigens 2011, 77:239-243.
252. Invernizzi P., Miozzo M., Battezzati P.M., Bianchi I., Grati F.R., Simoni G., et al. Frequency of monosomy X in women with primary biliary cirrhosis. Lancet 2004, 363:533-535.
253. Invernizzi P., Pasini S., Selmi C., Gershwin M.E., Podda M. Female predominance and X chromosome defects in autoimmune diseases. J Autoimmun 2009, 33:12-16.
254. Miozzo M., Selmi C., Gentilin B., Grati F.R., Sirchia S., Oertelt S., et al. Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis. Hepatology 2007, 46:456-462.
255. Invernizzi P., Selmi C., Poli F., Frison S., Floreani A., Alvaro D., et al. Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: a multicenter study of 664 patients and 1992 healthy controls. Hepatology 2008, 48:1906-1912.
256. Bogdanos D.P., Baum H., Butler P., Rigopoulou E.I., Davies E.T., Ma Y., et al. Association between the primary biliary cirrhosis specific anti-sp100 antibodies and recurrent urinary tract infection. Dig Liver Dis 2003, 35:801-805.
257. Bogdanos D.P., Baum H., Grasso A., Okamoto M., Butler P., Ma Y., et al. Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. J Hepatol 2004, 40:31-39.
258. Bogdanos D.P., Pares A., Rodes J., Vergani D. Primary biliary cirrhosis specific antinuclear antibodies in patients from Spain. Am J Gastroenterol 2004, 99:763-764. [author reply 5].
259. Bogdanos D.P., Baum H., Okamoto M., Montalto P., Sharma U.C., Rigopoulou E.I., et al. Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its Lactobacillus mimic. Hepatology 2005, 42:458-465.
260. Bogdanos D.P., Baum H., Sharma U.C., Grasso A., Ma Y., Burroughs A.K., et al. Antibodies against homologous microbial caseinolytic proteases P characterise primary biliary cirrhosis. J Hepatol 2002, 36:14-21.
261. Fussey S.P., Lindsay J.G., Fuller C., Perham R.N., Dale S., James O.F., et al. Autoantibodies in primary biliary cirrhosis: analysis of reactivity against eukaryotic and prokaryotic 2-oxo acid dehydrogenase complexes. Hepatology 1991, 13:467-474.
262. Koutsoumpas A., Mytilinaiou M., Polymeros D., Dalekos G.N., Bogdanos D.P. Anti-Helicobacter pylori antibody responses specific for VacA do not trigger primary biliary cirrhosis-specific antimitochondrial antibodies. Eur J Gastroenterol Hepatol 2009, 21:1220.
263. Abdulkarim A.S., Petrovic L.M., Kim W.R., Angulo P., Lloyd R.V., Lindor K.D. Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae?. J Hepatol 2004, 40:380-384.
264. Burroughs A.K., Butler P., Sternberg M.J., Baum H. Molecular mimicry in liver disease. Nature 1992, 358:377-378.
265. Burroughs A.K., Rosenstein I.J., Epstein O., Hamilton-Miller J.M., Brumfitt W., Sherlock S. Bacteriuria and primary biliary cirrhosis. Gut 1984, 25:133-137.
266. Butler P., Hamilton-Miller J., Baum H., Burroughs A.K. Detection of M2 antibodies in patients with recurrent urinary tract infection using an ELISA and purified PBC specific antigens. Evidence for a molecular mimicry mechanism in the pathogenesis of primary biliary cirrhosis?. Biochem Mol Biol Int 1995, 35:473-485.
267. Butler P., Hamilton-Miller J.M., McIntyre N., Burroughs A.K. Natural history of bacteriuria in women with primary biliary cirrhosis and the effect of antimicrobial therapy in symptomatic and asymptomatic groups. Gut 1995, 36:931-934.
268. Butler P., Valle F., Hamilton-Miller J.M., Brumfitt W., Baum H., Burroughs A.K. M2 mitochondrial antibodies and urinary rough mutant bacteria in patients with primary biliary cirrhosis and in patients with recurrent bacteriuria. J Hepatol 1993, 17:408-414.
269. Donaldson P.T. Genetics of liver disease: immunogenetics and disease pathogenesis. Gut 2004, 53:599-608.
270. Floreani A., Bassendine M.F., Mitchison H., Freeman R., James O.F. No specific association between primary biliary cirrhosis and bacteriuria?. J Hepatol 1989, 8:201-207.
271. Leung P.S., Park O., Matsumura S., Ansari A.A., Coppel R.L., Gershwin M.E. Is there a relation between Chlamydia infection and primary biliary cirrhosis?. Clin Dev Immunol 2003, 10:227-233.
272. Mason A., Xu L., Shen Z., Fodera B., Joplin R., Neuberger J., et al. Patients with primary biliary cirrhosis make anti-viral and anti-mitochondrial antibodies to mouse mammary tumor virus. Gastroenterology 2004, 127:1863-1864. [author reply 4-5].
273. McNally R.J., Ducker S., James O.F. Are transient environmental agents involved in the cause of primary biliary cirrhosis? Evidence from space-time clustering analysis. Hepatology 2009, 50:1169-1174.
274. Selmi C., Balkwill D.L., Invernizzi P., Ansari A.A., Coppel R.L., Podda M., et al. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology 2003, 38:1250-1257.
275. Smyk D., Mytilinaiou M.G., Rigopoulou E.I., Bogdanos D.P. PBC triggers in water reservoirs, coal mining areas and waste disposal sites: from Newcastle to New York. Dis Markers 2010, 29:337-344.
276. Xu L., Sakalian M., Shen Z., Loss G., Neuberger J., Mason A. Cloning the human betaretrovirus proviral genome from patients with primary biliary cirrhosis. Hepatology 2004, 39:151-156.
277. Xu L., Shen Z., Guo L., Fodera B., Keogh A., Joplin R., et al. Does a betaretrovirus infection trigger primary biliary cirrhosis?. Proc Natl Acad Sci U S A 2003, 100:8454-8459.
278. Selmi C., De Santis M., Cavaciocchi F., Gershwin M.E. Infectious agents and xenobiotics in the etiology of primary biliary cirrhosis. Dis Markers 2010, 29:287-299.
279. Bogdanos D., Pusl T., Rust C., Vergani D., Beuers U. Primary biliary cirrhosis following Lactobacillus vaccination for recurrent vaginitis. J Hepatol 2008, 49:466-473.
280. Oldstone M.B. Molecular mimicry and autoimmune disease. Cell 1987, 50:819-820.
281. Bogdanos D.P., Choudhuri K., Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver 2001, 21:225-232.
282. Vergani D., Bogdanos D.P., Baum H. Unusual suspects in primary biliary cirrhosis. Hepatology 2004, 39:38-41.
283. Rigopoulou E.I., Smyk D.S., Matthews C.E., Billinis C., Burroughs A.K., Lenzi M., et al. Epstein-Barr virus as a trigger of autoimmune liver diseases. Adv Virol 2012, 2012:987471.
284. Vergani D., Choudhuri K., Bogdanos D.P., Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin Liver Dis 2002, 6:727-737.
285. Vergani D., Longhi M.S., Bogdanos D.P., Ma Y., Mieli-Vergani G. Autoimmune hepatitis. Semin Immunopathol 2009, 31:421-435.
286. Ahn J., Yang L., Paster B.J., Ganly I., Morris L., Pei Z., et al. Oral microbiome profiles: 16S rRNA pyrosequencing and microarray assay comparison. PLoS One 2011, 6:e22788.
287. Arumugam M., Raes J., Pelletier E., Le Paslier D., Yamada T., Mende D.R., et al. Enterotypes of the human gut microbiome. Nature 2011, 473:174-180.
288. Gill S.R., Pop M., Deboy R.T., Eckburg P.B., Turnbaugh P.J., Samuel B.S., et al. Metagenomic analysis of the human distal gut microbiome. Science 2006, 312:1355-1359.
289. Kurokawa K., Itoh T., Kuwahara T., Oshima K., Toh H., Toyoda A., et al. Comparative metagenomics revealed commonly enriched gene sets in human gut microbiomes. DNA Res 2007, 14:169-181.
290. Marchesi J.R. Human distal gut microbiome. Environ Microbiol 2011.
291. Qin J., Li R., Raes J., Arumugam M., Burgdorf K.S., Manichanh C., et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464:59-65.
292. Saulnier D.M., Riehle K., Mistretta T.A., Diaz M.A., Mandal D., Raza S., et al. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology 2011.
293. Siezen R.J., Kleerebezem M. The human gut microbiome: are we our enterotypes?. Microb Biotechnol 2011, 4:550-553.
294. Turnbaugh P.J., Hamady M., Yatsunenko T., Cantarel B.L., Duncan A., Ley R.E., et al. A core gut microbiome in obese and lean twins. Nature 2009, 457:480-484.
295. Nasidze I., Li J., Schroeder R., Creasey J.L., Li M., Stoneking M. High diversity of the saliva microbiome in Batwa pygmies. PLoS One 2011, 6:e23352.
296. Smyk D.S., Bogdanos D.P., Kriese S., Billinis C., Burroughs A.K., Rigopoulou E.I. Urinary tract infection as a risk factor for autoimmune liver disease: from bench to bedside. Clin Res Hepatol Gastroenterol 2011.
297. Varyani F.K., West J., Card T.R. An increased risk of urinary tract infection precedes development of primary biliary cirrhosis. BMC Gastroenterol 2011, 11:95.
298. Smyk D., Rigopoulou E.I., Baum H., Burroughs A.K., Vergani D., Bogdanos D.P. Autoimmunity and environment: am I at risk?. Clin Rev Allergy Immunol 2011.
299. Natesan M., Ulrich R.G. Protein microarrays and biomarkers of infectious disease. Int J Mol Sci 2010, 11:5165-5183.
300. Quintana F.J., Hagedorn P.H., Elizur G., Merbl Y., Domany E., Cohen I.R. Functional immunomics: microarray analysis of IgG autoantibody repertoires predicts the future response of mice to induced diabetes. Proc Natl Acad Sci U S A 2004, 101(Suppl. 2):14615-14621.
301. Larman H.B., Zhao Z., Laserson U., Li M.Z., Ciccia A., Gakidis M.A., et al. Autoantigen discovery with a synthetic human peptidome. Nat Biotechnol 2011, 29:535-541.
302. Drebber U., Kasper H.U., Ratering J., Wedemeyer I., Schirmacher P., Dienes H.P., et al. Hepatic granulomas: histological and molecular pathological approach to differential diagnosis-a study of 442 cases. Liver Int 2008, 28:828-834.
303. O'Donohue J., Fidler H., Garcia-Barcelo M., Nouri-Aria K., Williams R., McFadden J. Mycobacterial DNA not detected in liver sections from patients with primary biliary cirrhosis. J Hepatol 1998, 28:433-438.
304. Tanaka A., Prindiville T.P., Gish R., Solnick J.V., Coppel R.L., Keeffe E.B., et al. Are infectious agents involved in primary biliary cirrhosis? A PCR approach. J Hepatol 1999, 31:664-671.
305. Vilagut L., Pares A., Rodes J., Vila J., Vinas O., Gines A., et al. Mycobacteria-related to the aetiopathogenesis of primary biliary cirrhosis?. J Hepatol 1996, 24:125.
306. Chen E.C., Miller S.A., DeRisi J.L., Chiu C.Y. Using a pan-viral microarray assay (Virochip) to screen clinical samples for viral pathogens. J Vis Exp 2011.
307. Kistler A., Avila P.C., Rouskin S., Wang D., Ward T., Yagi S., et al. Pan-viral screening of respiratory tract infections in adults with and without asthma reveals unexpected human coronavirus and human rhinovirus diversity. J Infect Dis 2007, 196:817-825.
308. Nakamura S., Nakaya T., Iida T. Metagenomic analysis of bacterial infections by means of high-throughput DNA sequencing. Exp Biol Med (Maywood) 2011, 236:968-971.
309. Tang P., Chiu C. Metagenomics for the discovery of novel human viruses. Future Microbiol 2010, 5:177-189.
310. Moore R.A., Warren R.L., Freeman J.D., Gustavsen J.A., Chenard C., Friedman J.M., et al. The sensitivity of massively parallel sequencing for detecting candidate infectious agents associated with human tissue. PLoS One 2011, 6:e19838.
311. Broome U., Scheynius A., Hultcrantz R. Induced expression of heat-shock protein on biliary epithelium in patients with primary sclerosing cholangitis and primary biliary cirrhosis. Hepatology 1993, 18:298-303.
312. Singhal S., Dian D., Keshavarzian A., Fogg L., Fields J.Z., Farhadi A. The role of oral hygiene in inflammatory bowel disease. Dig Dis Sci 2011, 56:170-175.
313. Ochoa-Reparaz J., Mielcarz D.W., Ditrio L.E., Burroughs A.R., Foureau D.M., Haque-Begum S., et al. Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis. J Immunol 2009, 183:6041-6050.
314. Helenius L.M., Meurman J.H., Helenius I., Kari K., Hietanen J., Suuronen R., et al. Oral and salivary parameters in patients with rheumatic diseases. Acta Odontol Scand 2005, 63:284-293.
315. Mason A.L., Xu L., Guo L., Munoz S., Jaspan J.B., Bryer-Ash M., et al. Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet 1998, 351:1620-1624.
316. Alvaro D., Alpini G., Onori P., Franchitto A., Glaser S.S., Le Sage G., et al. Alfa and beta estrogen receptors and the biliary tree. Mol Cell Endocrinol 2002, 193:105-108.
317. Cunningham M., Gilkeson G. Estrogen receptors in immunity and autoimmunity. Clin Rev Allergy Immunol 2011, 40:66-73.
318. Duvic M., Steinberg A.D., Klassen L.W. Effect of the anti-estrogen, Nafoxidine, on NZB/W autoimmune disease. Arthritis Rheum 1978, 21:414-417.
319. Holmdahl R. Estrogen exaggerates lupus but suppresses T-cell-dependent autoimmune disease. J Autoimmun 1989, 2:651-656.
320. Walker S.E. Estrogen and autoimmune disease. Clin Rev Allergy Immunol 2011, 40:60-65.
321. Mizutani T., Shinoda M., Tanaka Y., Kuno T., Hattori A., Usui T., et al. Autoantibodies against CYP2D6 and other drug-metabolizing enzymes in autoimmune hepatitis type 2. Drug Metab Rev 2005, 37:235-252.
322. Obermayer-Straub P., Strassburg C.P., Manns M.P. Autoimmune hepatitis. J Hepatol 2000, 32:181-197.
323. Garratty G. Drug-induced immune hemolytic anemia. Hematology Am Soc Hematol Educ Program 2009, 73-79.
324. Khokhar O., Gange C., Clement S., Lewis J. Autoimmune hepatitis and thyroiditis associated with rifampin and pyrazinamide prophylaxis: an unusual reaction. Dig Dis Sci 2005, 50:207-211.
325. Takasu N., Takara M., Komiya I. Rifampin-induced hypothyroidism in patients with Hashimoto's thyroiditis. N Engl J Med 2005, 352:518-519.
326. Ahrens N., Genth R., Salama A. Belated diagnosis in three patients with rifampicin-induced immune haemolytic anaemia. Br J Haematol 2002, 117:441-443.
327. Heurgue-Berlot A., Bernard-Chabert B., Diebold M.D., Thiefin G. Drug-induced autoimmune-like hepatitis: a case of chronic course after drug withdrawal. Dig Dis Sci 2011, 56:2504-2505. [author reply 5].
328. Bjornsson E., Talwalkar J., Treeprasertsuk S., Kamath P.S., Takahashi N., Sanderson S., et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010, 51:2040-2048.
329. Geddes M.R., Sinnreich M., Chalk C. Minocycline-induced dermatomyositis. Muscle Nerve 2010, 41:547-549.
330. Angulo J.M., Sigal L.H., Espinoza L.R. Minocycline induced lupus and autoimmune hepatitis. J Rheumatol 1999, 26:1420-1421.
331. Bachmeyer C., Cadranel J.F. Minocycline-induced lupus and autoimmune hepatitis: family autoimmune disorders as possible risk factors. Dermatology 2002, 205:185-186.
332. Bhat G., Jordan J., Sokalski S., Bajaj V., Marshall R., Berkelhammer C. Minocycline-induced hepatitis with autoimmune features and neutropenia. J Clin Gastroenterol 1998, 27:74-75.
333. Chamberlain M.C., Schwarzenberg S.J., Akin E.U., Kurth M.H. Minocycline-induced autoimmune hepatitis with subsequent cirrhosis. J Pediatr Gastroenterol Nutr 2006, 42:232-235.
334. Colmegna I., Perandones C.E., Chaves J.G. Minocycline induced lupus and autoimmune hepatitis. J Rheumatol 2000, 27:1567-1568.
335. Gough A., Chapman S., Wagstaff K., Emery P., Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ 1996, 312:169-172.
336. Healy J., Alexander B., Eapen C., Roberts-Thomson I.C. Minocycline-induced autoimmune hepatitis. Intern Med J 2009, 39:487-488.
337. Della Corte C., Carlucci A., Francalanci P., Alisi A., Nobili V. Autoimmune hepatitis type 2 following anti-papillomavirus vaccination in a 11-year-old girl. Vaccine 2011, 29:4654-4656.
338. Karali Z., Basaranoglu S.T., Karali Y., Oral B., Kilic S.S. Autoimmunity and hepatitis A vaccine in children. J Investig Allergol Clin Immunol 2011, 21:389-393.
339. Stubgen J.P. Neuromuscular disorders associated with hepatitis B vaccination. J Neurol Sci 2010, 292:1-4.
340. Cacoub P., Terrier B. Hepatitis B-related autoimmune manifestations. Rheum Dis Clin North Am 2009, 35:125-137.
341. Aron-Maor A., Shoenfeld Y. Vaccination and systemic lupus erythematosus: the bidirectional dilemmas. Lupus 2001, 10:237-240.
342. Borchers A.T., Keen C.L., Shoenfeld Y., Silva J., Gershwin M.E. Vaccines, viruses, and voodoo. J Investig Allergol Clin Immunol 2002, 12:155-168.
343. Chen R.T., Pless R., Destefano F. Epidemiology of autoimmune reactions induced by vaccination. J Autoimmun 2001, 16:309-318.
344. Cohen A.D., Shoenfeld Y. Vaccine-induced autoimmunity. J Autoimmun 1996, 9:699-703.
345. Nadler J.P. Multiple sclerosis and hepatitis B vaccination. Clin Infect Dis 1993, 17:928-929.
346. Ravel G., Christ M., Horand F., Descotes J. Autoimmunity, environmental exposure and vaccination: is there a link?. Toxicology 2004, 196:211-216.
347. Shoenfeld Y., Aharon-Maor A., Sherer Y. Vaccination as an additional player in the mosaic of autoimmunity. Clin Exp Rheumatol 2000, 18:181-184.
348. Shoenfeld Y., Aron-Maor A. Vaccination and autoimmunity-'vaccinosis': a dangerous liaison?. J Autoimmun 2000, 14:1-10.
349. Shoenfeld Y., Aron-Maor A., Tanai A., Ehrenfeld M. Bcg and autoimmunity: another two-edged sword. J Autoimmun 2001, 16:235-240.
350. Costenbader K.H., Gay S., Riquelme M.E., Iaccarino L., Doria A. Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases?. Autoimmun Rev 2011.
351. Arnson Y., Shoenfeld Y., Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 2010, 34:J258-J265.
352. Brusselle G.G., Joos G.F., Bracke K.R. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011, 378:1015-1026.
353. Simard J.F., Costenbader K.H. What can epidemiology tell us about systemic lupus erythematosus?. Int J Clin Pract 2007, 61:1170-1180.
354. Costenbader K.H., Karlson E.W. Cigarette smoking and autoimmune disease: what can we learn from epidemiology?. Lupus 2006, 15:737-745.
355. Rubin R.L., Hermanson T.M., Bedrick E.J., McDonald J.D., Burchiel S.W., Reed M.D., et al. Effect of cigarette smoke on autoimmunity in murine and human systemic lupus erythematosus. Toxicol Sci 2005, 87:86-96.
356. Asherson R.A., Shoenfeld Y., Jacobs P., Bosman C. An unusually complicated case of primary Sjogren's syndrome: development of transient "lupus-type" autoantibodies following silicone implant rejection. J Rheumatol 2004, 31:196-197.
357. Bar-Meir E., Eherenfeld M., Shoenfeld Y. Silicone gel breast implants and connective tissue disease-a comprehensive review. Autoimmunity 2003, 36:193-197.
358. Bar-Meir E., Teuber S.S., Lin H.C., Alosacie I., Goddard G., Terybery J., et al. Multiple autoantibodies in patients with silicone breast implants. J Autoimmun 1995, 8:267-277.
359. Vasey F.B., Zarabadi S.A., Seleznick M., Ricca L. Where there's smoke there's fire: the silicone breast implant controversy continues to flicker: a new disease that needs to be defined. J Rheumatol 2003, 30:2092-2094.
360. Vermeulen R.C., Scholte H.R. Rupture of silicone gel breast implants and symptoms of pain and fatigue. J Rheumatol 2003, 30:2263-2267.
361. Zandman-Goddard G., Blank M., Ehrenfeld M., Gilburd B., Peter J., Shoenfeld Y. A comparison of autoantibody production in asymptomatic and symptomatic women with silicone breast implants. J Rheumatol 1999, 26:73-77.
362. Hajdu S.D., Agmon-Levin N., Shoenfeld Y. Silicone and autoimmunity. Eur J Clin Invest 2011, 41:203-211.
363. Alotaibi S., Kennedy J., Tellier R., Stephens D., Banwell B. Epstein-Barr virus in pediatric multiple sclerosis. JAMA 2004, 291:1875-1879.
364. DeLorenze G.N., Munger K.L., Lennette E.T., Orentreich N., Vogelman J.H., Ascherio A. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch Neurol 2006, 63:839-844.
365. Goodin D.S. The causal cascade to multiple sclerosis: a model for MS pathogenesis. PLoS One 2009, 4:e4565.
366. Levin L.I., Munger K.L., O'Reilly E.J., Falk K.I., Ascherio A. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol 2010, 67:824-830.
367. Levin L.I., Munger K.L., Rubertone M.V., Peck C.A., Lennette E.T., Spiegelman D., et al. Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 2005, 293:2496-2500.
368. Lindberg C., Andersen O., Vahlne A., Dalton M., Runmarker B. Epidemiological investigation of the association between infectious mononucleosis and multiple sclerosis. Neuroepidemiology 1991, 10:62-65.
369. Lunemann J.D., Edwards N., Muraro P.A., Hayashi S., Cohen J.I., Munz C., et al. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 2006, 129:1493-1506.
370. Lunemann J.D., Huppke P., Roberts S., Bruck W., Gartner J., Munz C. Broadened and elevated humoral immune response to EBNA1 in pediatric multiple sclerosis. Neurology 2008, 71:1033-1035.
371. Lunemann J.D., Jelcic I., Roberts S., Lutterotti A., Tackenberg B., Martin R., et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med 2008, 205:1763-1773.
372. Operskalski E.A., Visscher B.R., Malmgren R.M., Detels R. A case-control study of multiple sclerosis. Neurology 1989, 39:825-829.
373. Peferoen L.A., Lamers F., Lodder L.N., Gerritsen W.H., Huitinga I., Melief J., et al. Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain 2010, 133:e137.
374. Sargsyan S.A., Shearer A.J., Ritchie A.M., Burgoon M.P., Anderson S., Hemmer B., et al. Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology 2010, 74:1127-1135.
375. Serafini B., Rosicarelli B., Franciotta D., Magliozzi R., Reynolds R., Cinque P., et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007, 204:2899-2912.
376. Thorley-Lawson D.A. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 2001, 1:75-82.
377. Warner H.B., Carp R.I. Multiple sclerosis and Epstein-Barr virus. Lancet 1981, 2:1290.
378. Willis S.N., Stadelmann C., Rodig S.J., Caron T., Gattenloehner S., Mallozzi S.S., et al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain 2009, 132:3318-3328.
379. Sriram S., Stratton C.W., Yao S., Tharp A., Ding L., Bannan J.D., et al. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol 1999, 46:6-14.
380. Challoner P.B., Smith K.T., Parker J.D., MacLeod D.L., Coulter S.N., Rose T.M., et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci U S A 1995, 92:7440-7444.
381. Dockrell D.H., Smith T.F., Paya C.V. Human herpesvirus 6. Mayo Clin Proc 1999, 74:163-170.
382. Chmielewska-Badora J., Cisak E., Dutkiewicz J. Lyme borreliosis and multiple sclerosis: any connection? A seroepidemic study. Ann Agric Environ Med 2000, 7:141-143.
383. Mancuso R., Delbue S., Borghi E., Pagani E., Calvo M.G., Caputo D., et al. Increased prevalence of varicella zoster virus DNA in cerebrospinal fluid from patients with multiple sclerosis. J Med Virol 2007, 79:192-199.
384. Ordonez G., Pineda B., Garcia-Navarrete R., Sotelo J. Brief presence of varicella-zoster viral DNA in mononuclear cells during relapses of multiple sclerosis. Arch Neurol 2004, 61:529-532.
385. Sotelo J., Martinez-Palomo A., Ordonez G., Pineda B. Varicella-zoster virus in cerebrospinal fluid at relapses of multiple sclerosis. Ann Neurol 2008, 63:303-311.
386. Birnbaum G., Kotilinek L., Albrecht L. Spinal fluid lymphocytes from a subgroup of multiple sclerosis patients respond to mycobacterial antigens. Ann Neurol 1993, 34:18-24.
387. Wroblewska Z., Gilden D., Devlin M., Huang E.S., Rorke L.B., Hamada T., et al. Cytomegalovirus isolation from a chimpanzee with acute demyelinating disease after inoculation of multiple sclerosis brain cells. Infect Immun 1979, 25:1008-1015.
388. Perron H., Garson J.A., Bedin F., Beseme F., Paranhos-Baccala G., Komurian-Pradel F., et al. Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. The Collaborative Research Group on Multiple Sclerosis. Proc Natl Acad Sci U S A 1997, 94:7583-7588.
389. Rasmussen H.B., Geny C., Deforges L., Perron H., Tourtelotte W., Heltberg A., et al. Expression of endogenous retroviruses in blood mononuclear cells and brain tissue from multiple sclerosis patients. Acta Neurol Scand Suppl 1997, 169:38-44.
390. Murray R.S., Brown B., Brian D., Cabirac G.F. Detection of coronavirus RNA and antigen in multiple sclerosis brain. Ann Neurol 1992, 31:525-533.
391. Stewart J.N., Mounir S., Talbot P.J. Human coronavirus gene expression in the brains of multiple sclerosis patients. Virology 1992, 191:502-505.
392. Ferrante P., Omodeo-Zorini E., Caldarelli-Stefano R., Mediati M., Fainardi E., Granieri E., et al. Detection of JC virus DNA in cerebrospinal fluid from multiple sclerosis patients. Mult Scler 1998, 4:49-54.
393. Stoner G.L., Agostini H.T., Ryschkewitsch C.F., Baumhefner R.W., Tourtellotte W.W. Characterization of JC virus DNA amplified from urine of chronic progressive multiple sclerosis patients. Mult Scler 1996, 1:193-199.
394. Forghani B., Cremer N.E., Johnson K.P., Ginsberg A.H., Likosky W.H. Viral antibodies in cerebrospinal fluid of multiple sclerosis and control patients: comparison between radioimmunoassay and conventional techniques. J Clin Microbiol 1978, 7:63-69.
395. ter Meulen V., Koprowski H., Iwasaki Y., Kackell Y.M., Muller D. Fusion of cultured multiple-sclerosis brain cells with indicator cells: presence of nucleocapsids and virions and isolation of parainfluenza-type virus. Lancet 1972, 2:1-5.
396. Haase A.T., Ventura P., Gibbs C.J., Tourtellotte W.W. Measles virus nucleotide sequences: detection by hybridization in situ. Science 1981, 212:672-675.
397. Jacobson S., Flerlage M.L., McFarland H.F. Impaired measles virus-specific cytotoxic T cell responses in multiple sclerosis. J Exp Med 1985, 162:839-850.
398. Alperovitch A., Berr C., Cambon-Thomsen A., Puel J., Dugoujon J.M., Ruidavets J.B., et al. Viral antibody titers, immunogenetic markers, and their interrelations in multiple sclerosis patients and controls. Hum Immunol 1991, 31:94-99.
399. Ortega-Hernandez O.D., Levin N.A., Altman A., Shoenfeld Y. Infectious agents in the pathogenesis of primary biliary cirrhosis. Dis Markers 2010, 29:277-286.
400. Shigematsu H., Shimoda S., Nakamura M., Matsushita S., Nishimura Y., Sakamoto N., et al. Fine specificity of T cells reactive to human PDC-E2 163-176 peptide, the immunodominant autoantigen in primary biliary cirrhosis: implications for molecular mimicry and cross-recognition among mitochondrial autoantigens. Hepatology 2000, 32:901-909.
401. Liu H.Y., Deng A.M., Zhang J., Zhou Y., Yao D.K., Tu X.Q., et al. Correlation of Chlamydia pneumoniae infection with primary biliary cirrhosis. World J Gastroenterol Jul 14, 2005, 11(26):4108-4110.
402. Bogdanos D.P., Pares A., Baum H., Caballeria L., Rigopoulou E.I., Ma Y., et al. Disease-specific cross-reactivity between mimicking peptides of heat shock protein of Mycobacterium gordonae and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis. J Autoimmun 2004, 22:353-362.
403. Vilagut L., Pares A., Vinas O., Vila J., Jimenez de Anta M.T., Rodes J. Antibodies to mycobacterial 65-kD heat shock protein cross-react with the main mitochondrial antigens in patients with primary biliary cirrhosis. Eur J Clin Invest 1997, 27:667-672.
404. Vilagut L., Vila J., Vinas O., Pares A., Gines A., Jimenez de Anta M.T., et al. Cross-reactivity of anti-Mycobacterium gordonae antibodies with the major mitochondrial autoantigens in primary biliary cirrhosis. J Hepatol 1994, 21:673-677.
405. Kita H., Matsumura S., He X.S., Ansari A.A., Lian Z.X., Van de Water J., et al. Analysis of TCR antagonism and molecular mimicry of an HLA-A0201-restricted CTL epitope in primary biliary cirrhosis. Hepatology 2002, 36:918-926.
406. Yamaguchi H., Miura H., Ohsumi K., Ishimi N., Taguchi H., Ishiyama N., et al. Detection and characterization of antibodies to bacterial heat-shock protein 60 in sera of patients with primary biliary cirrhosis. Microbiol Immunol 1994, 38:483-487.
407. Nickowitz R.E., Worman H.J. Autoantibodies from patients with primary biliary cirrhosis recognize a restricted region within the cytoplasmic tail of nuclear pore membrane glycoprotein Gp210. J Exp Med 1993, 178:2237-2242.
408. Stemerowicz R., Hopf U., Moller B., Wittenbrink C., Rodloff A., Reinhardt R., et al. Are antimitochondrial antibodies in primary biliary cirrhosis induced by R(rough)-mutants of Enterobacteriaceae?. Lancet 1988, 2:1166-1170.
409. Haruta I., Kikuchi K., Hashimoto E., Kato H., Hirota K., Kobayashi M., et al. A possible role of histone-like DNA-binding protein of Streptococcus intermedius in the pathogenesis of bile duct damage in primary biliary cirrhosis. Clin Immunol 2008, 127:245-251.
410. Sayers T.J., Baum H. Possible cross-reactivity of human anti-mitochondrial antibodies with membrane vesicles of Paracoccus denitrificans. Biochem Soc Trans 1976, 4:138-139.
411. Bogdanos D.P., Koutsoumpas A., Baum H., Vergani D. Borrelia burgdorferi: a new self-mimicking trigger in primary biliary cirrhosis. Dig Liver Dis 2006, 38:781-782. [author reply 2-3].
412. Harada K., Tsuneyama K., Sudo Y., Masuda S., Nakanuma Y. Molecular identification of bacterial 16S ribosomal RNA gene in liver tissue of primary biliary cirrhosis: is Propionibacterium acnes involved in granuloma formation?. Hepatology 2001, 33:530-536.
413. Berg C.P., Kannan T.R., Klein R., Gregor M., Baseman J.B., Wesselborg S., et al. Mycoplasma antigens as a possible trigger for the induction of antimitochondrial antibodies in primary biliary cirrhosis. Liver Int 2009, 29:797-809.
414. Jan G., Le Henaff M., Fontenelle C., Wroblewski H. Biochemical and antigenic characterisation of Mycoplasma gallisepticum membrane proteins P52 and P67 (pMGA). Arch Microbiol 2001, 177:81-90.
415. Ninomiya M., Ueno Y., Shimosegawa T. PBC: animal models of cholangiopathies and possible endogenous viral infections. Int J Hepatol 2012, 2012. (649290), (Electronic publication ahead of print 2011 Aug 8). 10.1155/2012/649290.
416. Zhang G., Chen M., Graham D., Subsin B., McDougall C., Gilady S., et al. Mouse mammary tumor virus in anti-mitochondrial antibody producing mouse models. J Hepatol 2011, 55:876-884.
417. Morshed S.A., Nishioka M., Saito I., Komiyama K., Moro I. Increased expression of Epstein-Barr virus in primary biliary cirrhosis patients. Gastroenterol Jpn 1992, 27:751-758.
418. Uzoegwu P., Baum H., Williamson J. Correlation of oligomycin-sensitive ATPase activity in trypanosomes with their content of an antigen to primary biliary cirrhosis. Cell Biol Int Rep 1984, 8:981-986.
419. Uzoegwu P.N., Baum H., Williamson J. The occurrence and localization in trypanosomes and other endo-parasites of an antigen cross-reacting with mitochondrial antibodies of primary biliary cirrhosis. Comp Biochem Physiol B 1987, 88:1181-1189.
420. Sakly W., Jeddi M., Ghedira I. Anti-Saccharomyces cerevisiae antibodies in primary biliary cirrhosis. Dig Dis Sci 2008, 53:1983-1987.